Jazz Pharmaceuticals vs BeOne Medicines
JAZZ and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and ONC compare
BeOne Medicines is the larger company, worth 39 times as much as Jazz Pharmaceuticals ($547B against $14.0B).
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 14.8× trailing earnings, against 861× for BeOne Medicines.
BeOne Medicines grew revenue faster over the last twelve months (34.3% versus 12.6% for Jazz Pharmaceuticals).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.4% compared with 10.7% at BeOne Medicines.
BeOne Medicines scores higher on the StockData Score (12 against 11 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | ONC |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $547B |
| Share price | $215.98 | $370.33 |
| Change, 1 year | 59.1% | 17.6% |
| Change, 5 years | 59.9% | 1.5% |
| Beta (5Y) | 0.55 | 1.07 |
| Employees | 2,890 | 12K |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 4 (better) | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 4 | 4 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.8× (better) | 861× |
| P/S | 3.0× (better) | 89.3× |
| P/B | 2.9× (better) | 106× |
| EV/EBITDA | 18.0× (better) | 504× |
| P/FCF | 8.8× (better) | 412× |
| FCF yield | 11.4% (better) | 0.24% |
| Fair value | $254.92 | $15.35 |
| Margin of safety | 15.3% (better) | −2313% |
| Growth | ||
| Revenue growth (TTM) | 12.6% | 34.3% (better) |
| Revenue growth, 5Y average | 12.5% | 76.8% (better) |
| Profitability | ||
| Gross margin | – | 88.9% |
| Operating margin | 19.5% (better) | 15.1% |
| Net margin | 20.4% (better) | 10.7% |
| FCF margin | 34.6% (better) | 21.7% |
| Return on equity | 22.1% (better) | 14.7% |
| Return on invested capital | 12.1% | 43.7% (better) |
| Financial health | ||
| Debt / equity | 0.91 | 0.22 (better) |
| Net debt / EBITDA | 2.40 (better) | −3.67 |
| Interest coverage | – | 8.7× |
| Current ratio | 1.78 | 3.40 (better) |
| Altman Z-score | 2.35 | 82.54 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.2% | 2.4% |
| Held by insiders | 3.4% | 13.9% |
| Insider net buying, 12 months | −$68.0M (better) | −$369M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.7% | – |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.